News
Amneal Launches PEMRYDI RTU, The First Ready-To-Use Version Of Important Oncology Injectable Medicine
16 Apr 24
Biotech, News, General
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
5 Apr 24
News, Legal
Amneal Receives FDA Approval For Ciprofloxacin And Dexamethasone Otic Suspension
25 Mar 24
Biotech, News, FDA, General
Piper Sandler Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $8
21 Mar 24
News, Price Target, Analyst Ratings
Goldman Sachs Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $6.25
4 Mar 24
News, Price Target, Analyst Ratings
Why Is Generic Drug-Focused Amneal Pharmaceuticals Stock Trading Lower Friday?
1 Mar 24
Earnings, News, Guidance, Health Care, Movers, General
Earnings Scheduled For March 1, 2024
1 Mar 24
Earnings
Amneal Pharmaceuticals: Q4 Earnings Insights
1 Mar 24
Earnings
Amneal Pharmaceuticals Q4 Adjusted EPS $0.14 Beats $0.09 Estimate, Sales $616.98M Miss $634.23M Estimate
1 Mar 24
Earnings, News
Earnings Outlook For Amneal Pharmaceuticals
29 Feb 24
Earnings
Amneal Enters Into Exclusive European Licensing Agreement With Zambon Biotech For IPX203
27 Feb 24
Biotech, News, Global, General
Amneal Reports Complete Response Resubmission To FDA For IPX203 New Drug Application
8 Feb 24
News, FDA
Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $8
29 Jan 24
News, Price Target, Analyst Ratings
Press releases
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
16 Apr 24
Press Releases
Amneal to Report First Quarter 2024 Results on May 3, 2024
10 Apr 24
Press Releases
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
25 Mar 24
Press Releases
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results
1 Mar 24
Press Releases
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203
27 Feb 24
Press Releases
Amneal to Participate at Upcoming Investor Conference
13 Feb 24
Press Releases
Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
31 Jan 24
Press Releases
Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203
25 Jan 24
Press Releases